Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (AZNCF)
OTHER OTC:AZNCF
AZNCF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$120.64 - $175.00
Previous CloseN/A
Volume3.14K
Average Volume (3M)5.16K
Market Cap
£242.79B
Enterprise Value$176.61B
Total Cash (Recent Filing)£7.11B
Total Debt (Recent Filing)£32.84B
Price to Earnings (P/E)30.1
Beta0.20
Next Earnings
Nov 06, 2025EPS Estimate
2.28Last Dividend Ex-Date
Aug 08, 2025Dividend Yield1.95%
Share Statistics
EPS (TTM)2.17
Shares Outstanding1,550,682,600
10 Day Avg. Volume6,055
30 Day Avg. Volume5,163
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£180.12Price Target Upside11.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Drug Development SuccessAstraZeneca's upcoming Phase 3 data for Baxdrostat is being closely watched by analysts.
Market PotentialThe 2034 risk-adjusted estimates for non-oncology phase 3 read-outs are at least 35% higher than consensus, indicating strong potential value.
Bears Say
Operational ExpensesInvestor focus is expected on SG&A expense progression, which showed a 150bps improvement compared to 1Q24.
Revenue ChallengesChina VBP inclusion for Farxiga and Lynparza have been flagged as potential headwinds to margins.
AstraZeneca News
AZNCF FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest stock price was $120.64 and its highest was $175.00 in the past 12 months.
What is AstraZeneca PLC’s market cap?
AstraZeneca PLC’s market cap is £242.79B.
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Nov 06, 2025 which is in 66 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Jul 29, 2025. The company reported $2.17 earnings per share for the quarter, beating the consensus estimate of $2.148 by $0.022.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Semiannually dividend of $1.025 which represents an annual dividend yield of 1.95%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is 2.28.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,682,600 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of $2.17 in its last earnings report, beating expectations of $2.148. Following the earnings report the stock price went up 4.427%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in AZNCF
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£180.12 (11.79% Upside)
£180.12 (11.79% Upside)
Insider Transactions
Sold Shares
Worth £1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.25%
12-Months-Change
Fundamentals
Return on Equity
20.09%
Trailing 12-Months
Asset Growth
-0.61%
Trailing 12-Months
Company Description
AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZNCF Stock 12 Month Forecast
Average Price Target
$180.12
▲(11.79% Upside)
Technical Analysis
GlaxoSmithKline
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Haleon PLC
―
Ownership Overview
0.03% Insiders
12.61% Mutual Funds
0.01% Other Institutional Investors
77.81% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---